publication . Article . 2007

Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain

Piñol, Carme; Roze, Stephane; Valentine, William; Evers, Thomas;
Open Access Spanish
  • Published: 01 Apr 2007
  • Publisher: Ediciones Doyma, S.L.
Abstract
Objetivos: Evaluar el coste-efectividad de la adición de acarbosa al tratamiento de pacientes con diabetes mellitus tipo 2 (DM2) en España. Métodos: Se utilizó el CORE Diabetes Model (modelo de simulación informática publicado y validado) para proyectar a largo plazo los resultados clínicos y de costes de la DM2. Las probabilidades de transición y los riesgos se obtuvieron de distintas publicaciones. Los efectos del tratamiento y las características basales de la cohorte se obtuvieron de un metaanálisis. Los costes directos se extrajeron de diversas publicaciones y se proyectaron a lo largo de la vida de los pacientes bajo la perspectiva del Sistema Nacional de ...
Subjects
free text keywords: Coste efectividad, Diabetes tipo 2, Acarbosa, Años de vida ajustados por calidad, Cost-effectiveness, Type 2 diabetes, Acarbose, Quality-adjusted life years, Public Health, Environmental and Occupational Health, Indirect costs, medicine.disease, medicine, Gerontology, Quality-adjusted life year, Willingness to pay, Environmental health, Life expectancy, Pediatrics, medicine.medical_specialty, business.industry, business, medicine.drug, Placebo, Cohort
Related Organizations
33 references, page 1 of 3

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53. [OpenAIRE]

2. Jönsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002;45:5S-12S.

3. Mata M, Antoñanzas F, Tafalla M, Sanz P. El coste de la diabetes en España. El estudio CODE-2. Gac Sanit. 2002;16:511- 20.

4. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care. 1999;22:960-4.

5. The UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.

6. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, et al. Hemoglobin A1c measurements over nearly two decades: substaining comparable values throughout the Diabetes Control and Complications trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem. 2005;51:753-8.

7. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven longterm studies. Eur Heart J. 2004;25:10-6.

8. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: projecting longterm clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20 Suppl 1:5-26.

9. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20 Suppl 1:27-40.

10. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR, UKPDS study group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci. 2001;101:671-9.

11. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.

12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486- 94. [OpenAIRE]

13. Orden Ministerial de 23 de octubre de 2003, por la que se determinan los nuevos conjuntos de presentaciones de especialidades farmacéuticas y se aprueban los correspondientes precios de referencia. BOE. 2003;256:38168-205.

14. Bastida J, Aguilar S, Álvarez M, González D. The economic burden of stroke in Spain. Value in Health. 2003;6:614.

15. Darbà J, Izquierdo I, Pontes C, Navas C, Rovira J. Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. Pharmacoeconomics. 2002;20:195-201. [OpenAIRE]

33 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2007

Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain

Piñol, Carme; Roze, Stephane; Valentine, William; Evers, Thomas;